[Collateral damage and hospital infections].

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Context:

• Antibiotic therapy exerts ecological pressure, selecting for resistant microorganisms.
• Hospital-acquired infections, particularly bacteremias and pneumonias, are significant causes of morbidity and mortality.
• A high prevalence of multi-drug resistant pathogens complicates the treatment of nosocomial infections.

Purpose:

• To explore the mechanisms and consequences of antibiotic-induced microbial resistance.
• To evaluate current treatment strategies for hospital-acquired infections.
• To assess the efficacy of combined antibiotic therapies in managing resistant pathogens.

Summary:

• Collateral damage from antibiotics includes the selection and proliferation of multi-resistant microorganisms.
• Microbial resistance is driven by gene transfer elements like integrons and transposons, exacerbated by hospital environments.
• Combined therapy with carbapenems and glycopeptides shows promise in reducing treatment failures and resistance.
• Treatment optimization involves tailoring empirical broad-spectrum antibiotic use to local resistance patterns.

Impact:

• Reduced incidence of inadequate treatment onset for nosocomial infections.
• Decreased risk of further microbial resistance development.
• Shorter treatment durations and lower healthcare costs associated with hospital-acquired infections.
• Improved patient outcomes through optimized antimicrobial pharmacodynamics and de-escalation strategies.